For COVID-Impacted Studies, US FDA Loosens Video Conferencing But Tightens Home Infusion Guidance

Also, use of alternative labs or imaging centers depends upon type of assessment and reason it is being performed, FDA's revised guidance states; missed milestones for postmarketing studies required under accelerated approval will need to be justified.